Harvard Bioscience (HBIO) Liabilities and Shareholders Equity (2010 - 2026)

Harvard Bioscience (HBIO) has 17 years of Liabilities and Shareholders Equity data on file, last reported at $77.9 million in Q1 2026.

• On a quarterly basis, Liabilities and Shareholders Equity fell 2.33% year-over-year to $77.9 million in Q1 2026; TTM through Mar 2026 was $316.1 million, a 32.26% decrease from a year earlier, with the FY2025 full-year figure at $80.1 million, down 36.77% from the prior year.
• Liabilities and Shareholders Equity for Q1 2026 stood at $77.9 million, down from $80.1 million in the prior quarter.
• Over the last five years, Liabilities and Shareholders Equity for HBIO reached as high as $158.0 million in Q1 2022 and fell as low as $77.9 million in Q1 2026.
• Historically, Liabilities and Shareholders Equity has averaged $122.8 million across 5 years, with a median of $133.2 million in 2024.
• Across the five-year window, Liabilities and Shareholders Equity climbed 4.49% in 2022 and sank 40.57% in 2025, its largest moves.
• Year by year, Liabilities and Shareholders Equity stood at $145.4 million in 2022, then declined by 5.5% to $137.4 million in 2023, then dropped by 7.81% to $126.6 million in 2024, then slumped by 36.77% to $80.1 million in 2025, then declined by 2.66% to $77.9 million in 2026.
• Per Business Quant data, the three most recent Liabilities and Shareholders Equity figures were $77.9 million in Q1 2026, $80.1 million in Q4 2025, and $78.0 million in Q3 2025.